DK1066049T3 - Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse - Google Patents

Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse

Info

Publication number
DK1066049T3
DK1066049T3 DK99910418T DK99910418T DK1066049T3 DK 1066049 T3 DK1066049 T3 DK 1066049T3 DK 99910418 T DK99910418 T DK 99910418T DK 99910418 T DK99910418 T DK 99910418T DK 1066049 T3 DK1066049 T3 DK 1066049T3
Authority
DK
Denmark
Prior art keywords
peptides
preparation
methods
pharmaceutical compositions
sustained release
Prior art date
Application number
DK99910418T
Other languages
Danish (da)
English (en)
Inventor
Marc Pellet
Frederic Bismuth
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of DK1066049T3 publication Critical patent/DK1066049T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK99910418T 1998-03-25 1999-03-22 Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse DK1066049T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803667A FR2776520B1 (fr) 1998-03-25 1998-03-25 Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
PCT/FR1999/000667 WO1999048517A1 (fr) 1998-03-25 1999-03-22 Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation

Publications (1)

Publication Number Publication Date
DK1066049T3 true DK1066049T3 (da) 2003-09-29

Family

ID=9524472

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910418T DK1066049T3 (da) 1998-03-25 1999-03-22 Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse

Country Status (19)

Country Link
US (1) US6503534B1 (ja)
EP (1) EP1066049B1 (ja)
JP (1) JP4162381B2 (ja)
AR (1) AR020062A1 (ja)
AT (1) ATE241377T1 (ja)
AU (1) AU756148B2 (ja)
CA (1) CA2324901C (ja)
CZ (1) CZ298941B6 (ja)
DE (1) DE69908326T2 (ja)
DK (1) DK1066049T3 (ja)
ES (1) ES2200507T3 (ja)
FR (1) FR2776520B1 (ja)
HU (1) HU228903B1 (ja)
IL (2) IL138533A0 (ja)
NO (1) NO324621B1 (ja)
PL (1) PL197775B1 (ja)
PT (1) PT1066049E (ja)
RU (1) RU2224538C2 (ja)
WO (1) WO1999048517A1 (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JP4898118B2 (ja) * 2002-09-27 2012-03-14 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 徐放性を有する薬剤学的に活性なペプチドのための投与形及びそれらの製造方法
DE04758472T1 (de) * 2003-03-26 2005-06-23 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung eines pharmazeutischen wirkstoffs mit hochspezifischer oberfläche
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
TWI353250B (en) * 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
EP1703916A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
CA2552757A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
US8088197B2 (en) * 2005-07-28 2012-01-03 Kilimanjaro Energy, Inc. Removal of carbon dioxide from air
GB0517627D0 (en) 2005-08-30 2005-10-05 Tyco Electronics Ltd Uk Bus-bar and connector
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
JP5452230B2 (ja) * 2006-12-21 2014-03-26 ストライカー コーポレイション 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
RU2009140731A (ru) * 2007-04-04 2011-05-10 Тератекнолоджиз Инк. (Ca) Фармацевтические составы, содержащие молекулы ghrh
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
PL2421545T3 (pl) 2009-04-23 2018-05-30 Jbs United Animal Health Ii Llc Sposób i kompozycja do synchronizacji czasu inseminacji
CA2759888A1 (en) 2009-05-01 2010-11-04 Tine Kold Olesen Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
BR112012003327A2 (pt) 2009-08-14 2017-06-06 Phasebio Pharmaceuticals Inc peptídeos intestinais vasoativos modificados
ES2677012T3 (es) * 2010-01-13 2018-07-27 Ipsen Pharma S.A.S. Proceso para la preparación de composiciones farmacéuticas para la liberación sostenida de análogos de somatostatina
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
CN107569456A (zh) 2012-06-01 2018-01-12 辉凌公司 制造地加瑞克
CN104994865A (zh) 2012-11-28 2015-10-21 杰碧斯联合动物健康第二有限责任公司 用于同步小母猪的授精时间的方法
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
CN107427556B (zh) 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
WO2020170185A1 (en) * 2019-02-21 2020-08-27 Dr. Reddy’S Laboratories Limited Substantially pure lanreotide or its salt & process thereof
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
IL312678A (en) * 2021-11-22 2024-07-01 SpecGx LLC A sustained-release injectable medicinal compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030551C (en) * 1989-05-01 1998-08-25 Wayne Gombotz Process for producing small particles of biologically active molecules
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions

Also Published As

Publication number Publication date
ATE241377T1 (de) 2003-06-15
RU2224538C2 (ru) 2004-02-27
AU2938499A (en) 1999-10-18
AR020062A1 (es) 2002-04-10
DE69908326T2 (de) 2004-03-25
ES2200507T3 (es) 2004-03-01
CZ20003432A3 (cs) 2001-02-14
HUP0101545A3 (en) 2001-12-28
DE69908326D1 (de) 2003-07-03
FR2776520A1 (fr) 1999-10-01
EP1066049A1 (fr) 2001-01-10
JP2002507578A (ja) 2002-03-12
FR2776520B1 (fr) 2000-05-05
IL138533A (en) 2006-12-31
CA2324901A1 (fr) 1999-09-30
CA2324901C (fr) 2012-01-24
IL138533A0 (en) 2001-10-31
EP1066049B1 (fr) 2003-05-28
NO20004741L (no) 2000-11-22
JP4162381B2 (ja) 2008-10-08
HUP0101545A1 (hu) 2001-11-28
PT1066049E (pt) 2003-10-31
HU228903B1 (en) 2013-06-28
US6503534B1 (en) 2003-01-07
CZ298941B6 (cs) 2008-03-19
NO20004741D0 (no) 2000-09-22
PL343005A1 (en) 2001-07-30
AU756148B2 (en) 2003-01-02
NO324621B1 (no) 2007-11-26
PL197775B1 (pl) 2008-04-30
WO1999048517A1 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
DK1326585T4 (da) Fremgangsmåde til fremstilling af pulverformuleringer
NO992339D0 (no) Farmas°ytiske formuleringer
DK1042355T3 (da) 11beta-halogen-7alfa-substituerede estratriener, fremgangsmåde til fremstilling af farmaceutiske præparater, der indeholder disse 11beta-halogen-7alfa-substituerede estratriener, samt deres anvendelse til fremstilling af lægemidler
NO20011613L (no) Sammensetninger og fremgangsmåte for WT1-spesifikk immunterapi
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1152765T3 (da) Ethanolat af azithromycin, fremgangsmåde til fremstilling og farmaceutiske sammensætninger deraf
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
EE200100134A (et) Kiiresti vabastav tablett
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
DK1181397T3 (da) Rhodium-elektrokatalysator og fremgangsmåde til fremstilling af denne
DK0991654T3 (da) Hidtil ukendte derivater af 2-(iminomethyl)aminophenyl, deres fremstilling, deres anvendelse til medikamenter og farmaceutiske præparater indeholdende samme
DK0973763T3 (da) Hidtil ukendte 2-(iminomethyl)aminophenylderivater, fremstilling af disse, anvendelse af disse i egenskab af lægemidler og farmaceutiske præparater indeholdende disse
DK1265482T3 (da) Vandige formulationer og fremgangsmåde til fremstilling af samme
DK0977812T3 (da) Asfaltsammensætninger og fremgangsmåder til fremstilling deraf
DK0991415T3 (da) Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
IS2841B (is) Samstæða hluta og lyfjasamsetningar
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
DK1015433T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oler, fremgangsmåder til fremstilling af disse og deres anvendelse som lægemidler
NO20022022L (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse